|
THROMBOCYTOPENIA 6
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies.
|
26936507 |
2016 |
|
THROMBOCYTOPENIA 6
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies.
|
26936507 |
2016 |
|
THROMBOCYTOPENIA 6
|
0.700 |
GermlineCausalMutation
|
disease |
ORPHANET |
A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies.
|
26936507 |
2016 |
|
THROMBOCYTOPENIA 6
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
THROMBOCYTOPENIA 6
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Status Epilepticus
|
0.500 |
Biomarker
|
disease |
RGD |
Increase in tyrosine phosphorylation of the NMDA receptor following the induction of status epilepticus.
|
16600505 |
2006 |
|
Status Epilepticus
|
0.500 |
Biomarker
|
disease |
CTD_human |
Increase in tyrosine phosphorylation of the NMDA receptor following the induction of status epilepticus.
|
16600505 |
2006 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
SRC is aberrantly over-expressed and activated in more than 80% of colorectal cancer (CRC) patients, therefore regulation of its stability and activity is essential.
|
31208298 |
2020 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
CCR2 Chemokine Receptors Enhance Growth and Cell-Cycle Progression of Breast Cancer Cells through SRC and PKC Activation.
|
30446625 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Under the supervision of medical oncologists and utilizing several literature resources for the parameter values, the effectiveness of treatment combinations for breast cancer specified with different sequences (i.e., SRC, SCR, CR, RC) are compared by tracking the number of cancer cells at the end of each treatment modality.
|
30389401 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
SRC-1 has been shown to play an important role in the progression of breast cancer and prostate cancer.
|
30532986 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor receptor (EGFR) and proto-oncogene tyrosine-protein kinase Src (c-Src) are critical components of the signaling pathways that are associated with breast cancer.
|
31430896 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E and SRC mutations are important molecular markers which can predict prognosis and conversion surgery in Stage IV CRC.
|
30792536 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
SRC-1 has been shown to play an important role in the progression of breast cancer and prostate cancer.
|
30532986 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CCR2 Chemokine Receptors Enhance Growth and Cell-Cycle Progression of Breast Cancer Cells through SRC and PKC Activation.
|
30446625 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor receptor (EGFR) and proto-oncogene tyrosine-protein kinase Src (c-Src) are critical components of the signaling pathways that are associated with breast cancer.
|
31430896 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Under the supervision of medical oncologists and utilizing several literature resources for the parameter values, the effectiveness of treatment combinations for breast cancer specified with different sequences (i.e., SRC, SCR, CR, RC) are compared by tracking the number of cancer cells at the end of each treatment modality.
|
30389401 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer.
|
29367763 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we report that FYN among SRC family kinases is required for the maintenance of basal type breast cancer subtype.
|
29348460 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since estrogen receptor-positive breast cancers typically express wild-type p53, these studies establish a rationale for p53 status to be predictive for effective SRC inhibitor treatment in this subtype of breast cancer.
|
29263157 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
BRC-31 cells display elevated focal adhesion kinase (FAK), SRC and extracellular signal-regulated (ERK2) phosphorylation relative to luminal breast cancer models.
|
29382358 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
The correlations between GoldScore fitness into FAK and SRC kinases and IC<sub>50</sub> against MCF-7 and A2780 cells were considerable (R<sup>2</sup>: 0.86-0.98).
|
29684708 |
2018 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thus, the present study suggests that activation of SRC is responsible for doxorubicin resistance in colon cancer.
|
29581735 |
2018 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we report that FYN among SRC family kinases is required for the maintenance of basal type breast cancer subtype.
|
29348460 |
2018 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer.
|
29367763 |
2018 |